A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of investigational vaccination regimens versus MENINGITEC™ or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old
Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine
Infections, Meningococcal
Phase 2
The results of study 104703 are summarised with study 104704 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.
June 2014